Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701759 | 0.85 | MAPK14 (0.60) | MAPK14KDM4EHTTCYP19A1MEN1 | |
| SCHEMBL4822705 | 0.85 | MAPK14 (0.72) | MAPK14HSPB1 | |
| SCHEMBL4811975 | 0.84 | MAPK14 (0.71) | MAPK14HSPB1 | |
| SCHEMBL4700691 | 0.83 | MAPK14 (0.65) | MAPK14HSPB1KMT2A | |
| SCHEMBL4819651 | 0.82 | MAPK14 (0.74) | MAPK14HSPB1 | |
| SCHEMBL4700556 | 0.82 | MAPK14 (0.69) | MAPK14HSPB1CYP19A1NAMPT | |
| SCHEMBL11091664 | 0.82 | SMN1; SMN2 (0.70) | KDM4EHTTCYP19A1MEN1KMT2A | |
| SCHEMBL4703306 | 0.82 | MAPK14 (0.64) | MAPK14HSPB1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL4821373 | 0.81 | MAPK14 (0.67) | MAPK14HSPB1 | |
| SCHEMBL4812042 | 0.78 | MAPK14 (0.68) | MAPK14HSPB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | claimed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | claimed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | claimed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | claimed |
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-27 | — | — | US | disclosed |
| EP-1436272-A1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033483-A1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 6/4885HSPB1 744/4885KDM4E 2722/4885 |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | MAPK1, MAPKAPK2, MAP3K1 | MAPK14 32/4885HSPB1 690/4885KDM4E 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.